Electromed’s (ELMD) Buy Rating Reaffirmed at Roth Capital

Roth Capital reiterated their buy rating on shares of Electromed (NYSE:ELMD) in a research report released on Thursday,Benzinga reports. They currently have a $36.00 price target on the stock, up from their prior price target of $35.00. Roth Capital also issued estimates for Electromed’s Q2 2026 earnings at $0.25 EPS, Q3 2026 earnings at $0.25 EPS, FY2026 earnings at $1.05 EPS and FY2027 earnings at $1.25 EPS.

A number of other equities research analysts have also issued reports on ELMD. Lake Street Capital assumed coverage on Electromed in a research note on Wednesday, August 27th. They issued a “buy” rating and a $36.00 price target for the company. Loop Capital set a $36.00 price objective on Electromed in a research note on Wednesday, August 27th. Finally, Zacks Research downgraded Electromed from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $36.50.

Electromed Stock Down 4.1%

NYSE:ELMD traded down $1.08 during trading hours on Thursday, hitting $25.27. 59,641 shares of the stock traded hands, compared to its average volume of 77,605. The company has a market cap of $211.66 million, a price-to-earnings ratio of 33.69 and a beta of 0.40. Electromed has a 1 year low of $17.73 and a 1 year high of $35.56. The stock has a 50 day moving average price of $24.62 and a 200 day moving average price of $22.00.

Insider Activity

In other Electromed news, Director Andrew Summers sold 3,153 shares of the stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $24.42, for a total transaction of $76,996.26. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 10.50% of the company’s stock.

Hedge Funds Weigh In On Electromed

Several large investors have recently made changes to their positions in ELMD. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Electromed in the 2nd quarter valued at $32,000. Financial Consulate Inc. purchased a new position in shares of Electromed in the third quarter worth approximately $37,000. State of Wyoming purchased a new position in shares of Electromed in the first quarter worth approximately $48,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Electromed during the second quarter valued at approximately $83,000. Finally, New York State Common Retirement Fund purchased a new stake in shares of Electromed in the 2nd quarter valued at approximately $103,000. Institutional investors own 40.82% of the company’s stock.

About Electromed

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.